Explore the Agenda
EEG Focus Day
Tuesday, September 15
Pre-Conference Workshop Day
Tuesday, September 15
Day One
Wednesday, September 16
Day Two
Thursday, September 17
9:00 am Chair’s Opening Remarks & Welcome
Honing Standardization, AI Utility, Dose & Patient Selection to Sharpen EEG Strategy for More Effective Mood Therapeutics
9:20 am Precision Psychiatry 2.0: Reimagining Frameworks, Tools & Clinical Pathways to Deliver Individualized Mental Health Care
- Positioning EEG as a scalable, translational biomarker, integrating neural signals with clinical and biological data to improve patient stratification and development decision-making
- Moving beyond symptom-based diagnoses by leveraging EEG-derived neurophysiological signatures to reduce heterogeneity and define biologically coherent subgroups
- Translating EEG, digital phenotyping, and AI-enabled analytics from research tools into deployable assets across clinical trials, endpoints, and real-world settings
- Aligning pharmacological and non-pharmacological interventions with EEG-informed neural biomarkers to guide target engagement, dose selection, and personalized treatment strategies
9:50 am EEG & AI to Identify Glutamatergic Responders: A Path to Overcoming Schizophrenia’s Etiologic Heterogeneity
- Highlight the limitations of DSM 5 diagnostic categories in schizophrenia and illustrate how etiologic heterogeneity has contributed to repeated failures of mechanistically novel drug candidates
- Demonstrate how EEG derived cortical activity patterns, paired with AI driven analysis, can provide a mechanistic basis for prospectively identifying patients whose glutamatergic pathology aligns with specific therapeutic mechanisms
- Present evidence from pomaglumetad Phase 3 re analysis showing that baseline EEG markers can identify a ~20% subgroup with substantial cognitive and negative symptom improvement, revealing responders concealed within a non significant overall trial
- Outline how ongoing work in schizophrenia and autism aims to validate EEG based responder identification across disorders with shared cortical circuit disruption, supporting a broader precision therapy framework
10:20 am Morning Break
10:50 am Decoding EEG Biomarkers with Biophysical Models: A New Evidence Layer for Neuropsychiatric Drug Development
- Explaining how biophysically grounded neural models link EEG signals to underlying cell‑ and circuit‑level mechanisms in health and neuropsychiatric disease
- Demonstrating how commonly used EEG biomarkers can be mechanistically interpreted to assess whether neurotherapeutics are acting on intended brain circuits
- Showing how EEG‑based circuit modeling can build earlier, translational evidence of target engagement and dosing before human clinical trials
11:20 am Roundtable Discussion: Toward True Standardization in EEG: Harmonizing Acquisition, Analysis & Data Infrastructure for Scalable, Regulatory-Ready Use
- Highlighting ongoing standardization efforts, such as IPEG’s recommendations, and how they provide a valuable foundation for common EEG acquisition and analysis practices
- Exploring opportunities to increase alignment across industry, academia, and technology partners to reduce variability and support more consistent analytical pipelines
- Discussing how emerging federated data infrastructures and shared EEG datasets can help establish reproducible, scalable analytical approaches across diverse clinical environments
- Identifying how unified standards and modern data frameworks can accelerate regulatory confidence, enhance trial comparability, and support broader adoption of EEG-based biomarkers
12:00 pm Lunch
Unlocking the Power of EEG & Sleep Biomarkers to Transform Diagnosis, Treatment Response & Precision Stratification
1:00 pm Using EEG Biomarkers to Accelerate Early Drug Development in Fragile X Syndrome & Autism
- Demonstrating how resting-state EEG can serve as a sensitive translational measure of target engagement in small first-in-human Fragile X and autism studies
- Presenting evidence of rapid normalization of disease-relevant EEG abnormalities following acute and short-erm treatment with novel synaptic therapeutics
- Pairing EEG biomarker improvements with clinically meaningful cognitive outcomes, including NIH Toolbox measures, to strengthen early proof-of-concept decisions
- Leveraging translational biomarker platforms to improve confidence in mechanism validation and subsequent clinical development decisions
1:30 pm Building Decision-Grade EEG Biomarkers to De-Risk Alzheimer’s & ALS Drug Development
- Using resting-state and auditory EEG biomarkers to detect pharmacodynamic effects and confirm target engagement in early brain disease studies
- Identifying biologically responsive patient subgroups to reduce heterogeneity and improve patient selection strategies
- Applying EEG-based responder identification approaches to support go/no-go decisions and progression into larger Phase 2 and 3 studies
- Exploring the role of neurophysiology biomarkers in advancing precision neuroscience and biomarker-informed trial design
2:00 pm Afternoon Networking Break
2:30 pm Roundtable Discussion: Establishing Clinically Meaningful EEG Signatures in Neuropsychiatry
- Which neuropsychiatric patient populations currently show the strongest evidence for EEG-based stratification?
- What have we learned from recent efforts to establish normative EEG datasets and biomarkers across depression, schizophrenia, sleep disorders and anxiety?
- Where are EEG biomarkers already influencing patient selection, dose rationale or efficacy assessment in clinical trials?
- What are the biggest barriers to regulatory acceptance and broader adoption of EEG endpoints?
- How should we combine EEG, digital biomarkers and clinical measures to advance precision neuropsychiatry?
3:10 pm Panel Discussion: Evaluating Unmet Needs in Sleep: Navigating EEG Utility & Limitations Across Complex Sleep Architecture
- Defining which facets of sleep (onset, maintenance, early awakening, quality, or EEG specific signals) truly matter as clinical biomarkers
- Understanding the practical and scientific limits of EEG in psychiatric sleep research: specificity, invasiveness, and placebo susceptibility
- How sponsors (orexin programs, sleep promoting or circadian targeting drugs) and EEG tech vendors interpret sleep architecture in different disease contexts
- Identifying core unmet needs in insomnia and sleep dysregulation across mood and psychiatric disorders, and what measurement innovation is required